ICDDTKZ26

Active not recruitingPhase NA

Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs

Improving the Diagnosis and Treatment of Cardiovascular Diseases in Kazakhstan by Introducing Correction of Metabolism With Glucagon-like Peptide 1 (GLP-1) Drugs

Lead sponsor

Nazarbayev University

Asset

Tirzepatide

Subcutaneous · GLP-1 / GIP dual

Listed sites

Recruiting sites

—

Enrollment

120

estimated

Study population

Heart failure, Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI ≥25•HbA1c 7-10.5%•EF ≤45%

Primary endpoint

•NT-proBNP, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07303556

Org study IDBR24993023

Timeline

Milestones

Study start2024-12-18actual

Primary completion2025-07-01actual

Study first posted2025-12-26actual

Last update posted2026-01-28actual

Study completion2026-11-01estimated

Assets

Investigational agents

Tirzepatide

Study populations

Who this study enrolls

Heart failureObesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Chronic heart failure with preserved ejection fraction (left ventricular ejection fraction not ≤ 45%)

•Type 2 diabetes mellitus (T2DM) with HbA1c level between ≥7.0% and ≤10.5%

•Ongoing treatment for T2DM (e.g., metformin and/or sulfonylureas, or basal insulin therapy)

•Stable body weight (±5%) for at least 3 months prior to screening

•Body mass index (BMI) ≥ 25 kg/m²

•Possible inclusion of patients with chronic pancreatitis in remission

•Aged 18 years or older, and not older than 75 years

•Both male and female participants

Exclusion criteria

•Type 1 diabetes mellitus

•Exacerbation of chronic pancreatitis

•Acute pancreatitis

•Proliferative diabetic retinopathy, diabetic maculopathy, or non-proliferative diabetic retinopathy

•History of bariatric (weight-loss) surgery or conditions associated with delayed gastric emptying

•Acute or chronic hepatitis

•Chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73 m²

•Myocardial infarction or stroke within the past 2 months

•Medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) in the participant or a first-degree relative

•Use of any other antidiabetic medications (except metformin and/or sulfonylureas and basal insulin) within the past 3 months

•Use of weight loss medications, including over-the-counter drugs, within the past 3 months

•History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorders within the past 2 years

•Healthy individuals (no cardiovascular or metabolic disease)

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Heart failure

Weight & body composition

Glycemic / diabetes

Patient-reported / QoL

Other (unclassified)

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Changes in clinical parameters associated with heart failure and type 2 diabetes mellitus

Time frame:Baseline to Week 24

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

1 endpoint

Secondary/protocol endpoint

Changes in metabolic associated with type 2 diabetes mellitus

Time frame:Baseline to Week 24

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Heart failure

2 endpoints

Primary/protocol endpoint

Change in NT-proBNP levels from baseline to Week 24

Time frame:Baseline to Week 24

NT-proBNP, change

change from baseline, improvement

Secondary/protocol endpoint

Changes clinical parameters associated with heart failure

Time frame:Baseline to Week 32

change from baseline, improvement

Patient-reported / QoL

1 endpoint

Secondary/protocol endpoint

Assessment of the Overall Condition of Patients Before and After the Study

Time frame:Baseline to Week 40

SF-36 total

change from baseline, improvement

Other (unclassified)

1 endpoint

Secondary/protocol endpoint/low confidence

Changes in clinical parameters associated with heart failure and type 2 diabetes mellitus

Time frame:Baseline to Week 24

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.